These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33082307)

  • 1. EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
    Paredes R; Kelly JR; Geary B; Almarzouq B; Schneider M; Pearson S; Narayanan P; Williamson A; Lovell SC; Wiseman DH; Chadwick JA; Jones NJ; Kustikova O; Schambach A; Garner T; Amaral FMR; Pierce A; Stevens A; Somervaille TCP; Whetton AD; Meyer S
    Cell Death Dis; 2020 Oct; 11(10):878. PubMed ID: 33082307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
    Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
    Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.
    White DJ; Unwin RD; Bindels E; Pierce A; Teng HY; Muter J; Greystoke B; Somerville TD; Griffiths J; Lovell S; Somervaille TC; Delwel R; Whetton AD; Meyer S
    PLoS One; 2013; 8(6):e66510. PubMed ID: 23776681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
    Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
    Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene
    Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
    Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
    Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
    Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.
    Senyuk V; Premanand K; Xu P; Qian Z; Nucifora G
    PLoS One; 2011; 6(6):e20793. PubMed ID: 21695170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Paredes R; Doleschall N; Connors K; Geary B; Meyer S
    Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
    Kataoka K; Kurokawa M
    Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
    Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
    Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
    Tanaka A
    Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
    Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
    PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation.
    Mizuno H; Koya J; Masamoto Y; Kagoya Y; Kurokawa M
    Cancer Sci; 2021 Oct; 112(10):4112-4126. PubMed ID: 34363719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.
    Laricchia-Robbio L; Nucifora G
    Blood Cells Mol Dis; 2008; 40(2):141-7. PubMed ID: 17913523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.
    Li F; He W; Geng R; Xie X
    Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
    Hinai AA; Valk PJ
    Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.